PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients
- PMID: 25736040
- DOI: 10.1007/s10549-015-3322-6
PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients
Abstract
We attempted to develop a highly sensitive and specific method for the detection of circulating tumor DNA (ctDNA) using a digital PCR (dPCR) assay for PIK3CA mutations (i.e., H1047R, E545K, and E542K) in primary breast cancer patients. The sensitivity of the dPCR assay for the mutant alleles was examined using cell lines with PIK3CA mutations and proved to be 0.01 %. Serum samples were collected pre-operatively from 313 stage I-III breast cancer patients, of whom 110 were found to have PIK3CA mutant tumors. The serum samples from these patients with PIK3CA mutant tumors were subjected to the dPCR assay, and 25 (22.7 %) were found to be positive. No PIK3CA mutant ctDNA was detected in the serum samples of 50 healthy women and 30 breast cancer patients with PIK3CA non-mutant tumors. The patients with PIK3CA mutant ctDNA were dichotomized into mutant ctDNA-high (ctDNA(high)) and ctDNA-low (ctDNA(low)) groups based on the median. The ctDNA(high) patients exhibited significantly shorter recurrence-free survival (RFS; P = 0.0002) and overall survival rates (OS; P = 0.0048) compared to those exhibited by the combined ctDNA(low) patient and ctDNA-free patient group. Multivariate analysis revealed that ctDNA(high) status significantly predicted poor RFS and OS and did so independently of conventional histological parameters. These results suggest that dPCR is a highly sensitive and specific method for the detection of PIK3CA mutant ctDNA and that ctDNA(high) but not ctDNA(low) status is a significant and independent prognostic factor for primary breast cancer patients.
Similar articles
-
Detection of TP53/PIK3CA Mutations in Cell-Free Plasma DNA From Metastatic Breast Cancer Patients Using Next Generation Sequencing.Clin Breast Cancer. 2016 Oct;16(5):418-423. doi: 10.1016/j.clbc.2016.05.004. Epub 2016 May 14. Clin Breast Cancer. 2016. PMID: 27265061
-
Association of preoperative and postoperative circulating tumour DNA (ctDNA) with PIK3CA gene mutation with risk of recurrence in patients with non-metastatic breast cancer.Surg Oncol. 2024 Jun;54:102060. doi: 10.1016/j.suronc.2024.102060. Epub 2024 Mar 5. Surg Oncol. 2024. PMID: 38603927
-
Detection of PIK3CA gene mutations with HRM analysis and association with IGFBP-5 expression levels in breast cancer.Asian Pac J Cancer Prev. 2014;15(21):9327-33. doi: 10.7314/apjcp.2014.15.21.9327. Asian Pac J Cancer Prev. 2014. PMID: 25422220
-
Use of cell free DNA in breast oncology.Biochim Biophys Acta. 2016 Apr;1865(2):266-74. doi: 10.1016/j.bbcan.2016.03.006. Epub 2016 Mar 22. Biochim Biophys Acta. 2016. PMID: 27012505 Review.
-
Precision Medicine for Breast Cancer Utilizing Circulating Tumor DNA: It Is in the Blood.Curr Treat Options Oncol. 2020 Sep 1;21(11):89. doi: 10.1007/s11864-020-00783-3. Curr Treat Options Oncol. 2020. PMID: 32875404 Review.
Cited by
-
An ultra-sensitive and rapid immunosensor for the onsite detection of circulating tumor DNA in breast cancer.Front Bioeng Biotechnol. 2024 Jul 12;12:1412598. doi: 10.3389/fbioe.2024.1412598. eCollection 2024. Front Bioeng Biotechnol. 2024. PMID: 39070168 Free PMC article.
-
Drainage of Tumor-Derived DNA into Sentinel Lymph Nodes in Breast Cancer Patients.Pathol Oncol Res. 2019 Oct;25(4):1635-1643. doi: 10.1007/s12253-019-00618-z. Epub 2019 Feb 25. Pathol Oncol Res. 2019. PMID: 30805870
-
Correlation between circulating cell-free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA-mutated metastatic breast cancer.Mol Oncol. 2018 Jun;12(6):925-935. doi: 10.1002/1878-0261.12305. Epub 2018 May 4. Mol Oncol. 2018. PMID: 29689598 Free PMC article.
-
Detection of PIK3CA Mutations in Plasma DNA of Colorectal Cancer Patients by an Ultra-Sensitive PNA-Mediated PCR.Mol Diagn Ther. 2017 Aug;21(4):443-451. doi: 10.1007/s40291-017-0269-9. Mol Diagn Ther. 2017. PMID: 28247181
-
Identifying Circulating Tumor DNA Mutation Profiles in Metastatic Breast Cancer Patients with Multiline Resistance.EBioMedicine. 2018 Jun;32:111-118. doi: 10.1016/j.ebiom.2018.05.015. Epub 2018 May 26. EBioMedicine. 2018. PMID: 29807833 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous